XENOTHERA

Their core work

XENOTHERA is a French clinical-stage biotech SME based in Nantes specializing in polyclonal immunotherapy — treatments that use a diverse mix of antibodies rather than a single engineered molecule to fight infection or disease. Their core technology platform produces xenogeneic polyclonal antibodies (antibodies derived from animal sources and adapted for human therapeutic use), with the aim of providing broader, more robust immune responses than conventional monoclonal approaches. Their most advanced asset, XAV-19, is a polyclonal antibody cocktail developed to treat severe COVID-19 by neutralizing SARS-CoV-2. As a founder-led SME, they drive their own clinical and regulatory pathway rather than operating as a service provider or contract research organization.

What they specialise in

How they've shifted over time

XENOTHERA's H2020 trajectory follows a textbook biotech proof-of-concept-to-clinical arc. In 2016, POLYBOOST was a small Phase 1 feasibility grant focused on validating the polyclonal immunotherapy concept — testing whether the platform was worth pursuing. By 2020, with BRIGHT, the company had moved from concept validation into a full €2.16M clinical development project targeting COVID-19 with a named therapeutic asset (XAV-19). The shift is not a change in scientific focus — polyclonal immunotherapy remained constant — but a dramatic escalation in ambition, clinical specificity, and funding scale, indicating the underlying platform matured significantly between the two projects.

XENOTHERA is moving up the clinical development ladder with a validated platform; future collaborations will likely involve late-stage clinical trials, regulatory strategy, or licensing of XAV-19 and next-generation polyclonal assets to larger pharma partners.

How they like to work

XENOTHERA coordinates all their projects and has never appeared as a simple participant — they lead their own R&D agenda and hold the IP. Their consortia are extremely small (just one recorded partner across both projects), which is typical of a clinical biotech protecting its proprietary platform while using EU grants to de-risk development costs. Anyone partnering with XENOTHERA should expect them to act as the scientific and commercial driver, not a supporting contributor.

XENOTHERA's H2020 network is deliberately minimal — one unique partner across two projects, all within France. This is characteristic of an IP-protective biotech SME that uses EU funding to advance its own pipeline rather than to build broad academic or industry networks.

What sets them apart

XENOTHERA occupies a rare niche: they are one of very few European SMEs with a proprietary xenogeneic polyclonal antibody platform advanced enough to reach clinical testing for an acute infectious disease like COVID-19. Unlike most antibody companies racing toward monoclonals, their polyclonal approach offers potential breadth-of-neutralization advantages against viral variants — a scientifically and commercially differentiated position. For a consortium or licensing partner looking for a clinical-stage biotech with a validated anti-infective biologic, XENOTHERA brings both the science and the regulatory track record.

Highlights from their portfolio

• BRIGHT
  At €2.16M under SME Phase 2, this is XENOTHERA's flagship project — a clinical-stage COVID-19 therapeutic development program for XAV-19, demonstrating the company's ability to advance a biologic from concept to named drug candidate.
• POLYBOOST
  As a Phase 1 feasibility grant (€50K), POLYBOOST is notable as the origin proof-of-concept that de-risked the polyclonal immunotherapy platform and enabled the much larger BRIGHT investment four years later.